Condition: Squamous Cell Carcinoma of Head and Neck · Sponsor: Johnson & Johnson Enterprise Innovation Inc.
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Moffit Cancer center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Hopital De La Cavale Blanche | Brest, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Hopital La Timone | Marseille, France | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219212